Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 8, Pages 2332
Publisher
MDPI AG
Online
2018-08-09
DOI
10.3390/ijms19082332
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study
- (2018) Ronan T. Gray et al. BMC CANCER
- Aspirine et cancer colorectal
- (2018) Adrien Grancher et al. BULLETIN DU CANCER
- Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
- (2018) Kathleen A. Cronin et al. CANCER
- Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH
- (2018) Jiping Wang et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Influence of smoking, body mass index and other factors on the preventive effect of nonsteroidal anti-inflammatory drugs on colorectal cancer risk
- (2018) Xiaoliang Wang et al. CANCER RESEARCH
- Abdominal Obesity is More Predictive of Advanced Colorectal Neoplasia Risk Than Overall Obesity in Men
- (2018) Nam Hee Kim et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Risk factors for advanced colorectal neoplasms in the proximal colon in 6218 subjects undergoing complete colonoscopy
- (2018) Hoyee W Hirai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4
- (2018) Suaka Kagbo-Kue et al. Cell and Bioscience
- Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis
- (2018) N. Jewel Samadder et al. JAMA Oncology
- Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas
- (2017) Wen-Chi L Chang et al. GUT
- Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status
- (2017) Tsuyoshi Hamada et al. JOURNAL OF CLINICAL ONCOLOGY
- The treatment of desmoid tumors associated with familial adenomatous polyposis: the results of a Japanese multicenter observational study
- (2017) Yasuhiro Inoue et al. SURGERY TODAY
- Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study
- (2017) Ronan T Gray et al. Clinical and Translational Gastroenterology
- Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway
- (2016) Issei Egashira et al. CANCER SCIENCE
- Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate
- (2016) Seth Septer et al. Familial Cancer
- Global patterns and trends in colorectal cancer incidence and mortality
- (2016) Melina Arnold et al. GUT
- Profound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal Tumorigenesis
- (2016) Mark Paul-Clark et al. PLoS One
- Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk
- (2015) Søren Friis et al. ANNALS OF INTERNAL MEDICINE
- NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications
- (2015) Ravinder Kodela et al. BIOCHEMICAL PHARMACOLOGY
- Sulindac, 3,3’-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis
- (2015) Angelo Pietro Femia et al. BMC CANCER
- Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients
- (2015) Daniel Robert Quast et al. Familial Cancer
- An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis
- (2015) Patrick M Lynch et al. GUT
- NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties
- (2015) Khosrow Kashfi et al. Redox Biology
- Molecular targets of aspirin and cancer prevention
- (2014) L Alfonso et al. BRITISH JOURNAL OF CANCER
- Molecular Pathways: Aspirin and Wnt Signaling--A Molecularly Targeted Approach to Cancer Prevention and Treatment
- (2014) M. K. Gala et al. CLINICAL CANCER RESEARCH
- Small bowel injury in low-dose aspirin users
- (2014) Hiroki Endo et al. JOURNAL OF GASTROENTEROLOGY
- Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer
- (2014) Wagdi Elsheikh et al. NITRIC OXIDE-BIOLOGY AND CHEMISTRY
- A comparative overview of general risk factors associated with the incidence of colorectal cancer
- (2013) Sabha Rasool et al. TUMOR BIOLOGY
- Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage
- (2013) Carlos Sostres et al. ARTHRITIS RESEARCH & THERAPY
- Aspirin and cancer risk: a quantitative review to 2011
- (2012) C. Bosetti et al. ANNALS OF ONCOLOGY
- Combination Aspirin and/or Calcium Chemoprevention with Colonoscopy in Colorectal Cancer Prevention: Cost-effectiveness Analyses
- (2012) B. C. Pence et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism
- (2012) Beatriz Carvalho et al. CELLULAR ONCOLOGY
- Non-Steroidal Anti-Inflammatory Drugs and Colorectal Cancer Risk in a Large, Prospective Cohort
- (2011) Elizabeth H Ruder et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Chemoprevention of Colon and Small Intestinal Tumorigenesis in APCMin/+ Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer Prevention
- (2011) A. Mohammed et al. Cancer Prevention Research
- Combination of Atorvastatin with Sulindac or Naproxen Profoundly Inhibits Colonic Adenocarcinomas by Suppressing the p65/ -Catenin/Cyclin D1 Signaling Pathway in Rats
- (2011) N. Suh et al. Cancer Prevention Research
- Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal Polyps
- (2011) T. Takayama et al. CLINICAL CANCER RESEARCH
- Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial
- (2011) Robert Benamouzig et al. GUT
- Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients
- (2010) M H Nieuwenhuis et al. BRITISH JOURNAL OF CANCER
- Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
- (2009) M. M. Bertagnolli et al. Cancer Prevention Research
- Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials
- (2009) Bernard F. Cole et al. JNCI-Journal of the National Cancer Institute
- Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial
- (2008) Frank L. Meyskens et al. Cancer Prevention Research
- Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance
- (2008) Michael B Sporn et al. Nature clinical practice. Oncology
- Aspirin and Folic Acid for the Prevention of Recurrent Colorectal Adenomas
- (2007) Richard F.A. Logan et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now